Biosimilar Production with IEX and Mixed-Mode Resins

antibodies therapeutics signature graphic

Overcoming the High Cost of Biosimilar Production

Despite being lower-cost alternatives to traditional biologics, production of biosimilar monoclonal antibodies (mAbs) can still be complex and costly due significantly to downstream processing. In this case study, learn how a combined ion exchange and mixed-mode purification workflow can perform as well as traditional Protein A solutions but at lower cost.

Read this case study to learn how:

  • Using a strong cation exchange resin for the affinity capture step can help minimize purification costs and overcome the limitations of Protein A capture
  • A combined ion exchange and mixed-mode purification workflow can help achieve greater product purity and increase dynamic binding capacity
  • Adopting alternative purification workflow models can improve process efficiency and economics of biosimilar production
bulletin_3493 thumbnail

Download the Article

Share a little information with us to access the entire article now.

 

Content you'll also find interesting

Recommended Features